• Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Press release

Invitation to presentation of MEDS Q3 2025 Interim Report on November 7, 2025

Meds Apotek

MEDS will publish its interim report for the third quarter of 2025 on November 7, 2025, at 07:30 CET. A webcast presentation will be held at: https://www.finwire.tv/webcast/meds-apotek/meds-2025/ for analysts, media, and investors at 10:00 CET the same day.

The report will be presented by Björn Thorngren, CEO and co-founder, and Nick Mendola, CFO.
The presentation will be conducted in English and broadcast live online. To register please email ir@meds.se at latest 09.00 CET on November 7, 2025. 

A recorded version of the presentation will also be available at: https://www.finwire.tv/webcast/meds-apotek/meds-2025/
 
Phone number for analysts: +46850163827, then enter the meeting ID: 81972913787 followed by #
 
Schedule on the 7th of November:

  • 07:30 CET – Publication of the Q3 report
  • 10:00 CET – Webcast and conference call with CEO Björn Thorngren and CFO Nick Mendola

 
For further information, please contact:
Frida Benno Hjerpe
MEDS Press & Investor Relations
E-mail: press@meds.se
Web: https://corporate.meds.se/


About MEDS
MEDS.se is a full-scale online pharmacy licensed by the Swedish Medical Products Agency. We provide both prescription and over-the-counter medicines for you, your family, and your pets.
In addition, MEDS offers a wide range of products in health, beauty, and wellness.

Certified advisor is FNCA.

Attachments


Invitation to presentation of MEDS Q3 2025 Interim Report on November 7, 2025